<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513485912</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513485912</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Hu</surname><given-names>Jiasheng</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513485912">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhu</surname><given-names>Xiongpeng</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513485912">1</xref>
<xref ref-type="corresp" rid="corresp1-0300060513485912"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Lu</surname><given-names>Quanyi</given-names></name>
<xref ref-type="aff" rid="aff2-0300060513485912">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0300060513485912"><label>1</label>Department of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, China</aff>
<aff id="aff2-0300060513485912"><label>2</label>Department of Haematology, Zhongshan Hospital of Xiamen, Xiamen, China</aff>
<author-notes>
<corresp id="corresp1-0300060513485912">Professor Xiongpeng Zhu, Department of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, 248 East Street, Licheng District, Quanzhou City 362000, Fujian Province, China. Email: <email>xiongpengzhu@163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>4</issue>
<fpage>1017</fpage>
<lpage>1026</lpage>
<history>
<date date-type="received"><day>10</day><month>2</month><year>2013</year></date>
<date date-type="accepted"><day>23</day><month>3</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec15-0300060513485912"><title>Objectives</title>
<p>To investigate the effects of γ-secretase inhibitor (GSI), a Notch signalling inhibitor, on the proliferation of multiple myeloma cells in vitro and its molecular mechanism of action.</p>
</sec>
<sec id="sec16-0300060513485912"><title>Methods</title>
<p>RPMI 8226 cells were treated with increasing concentrations of GSI (0–20 µmol/l) for 24–72 h. Proliferation was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay. Cell-cycle analysis was performed on RPMI 8226 cells treated with 0–10 µmol/l GSI for 48 h using flow cytometry. Expression of Notch signalling proteins (Notch1, Jagged 1 and Jagged 2), Bcl-2 and phosphorylated Akt (p-Akt) was determined using Western blotting in RPMI 8226 cells treated with various concentrations of GSI for various time periods.</p>
</sec>
<sec id="sec17-0300060513485912"><title>Results</title>
<p>GSI inhibited proliferation of RPMI 8226 cells in a concentration- and time-dependent manner by inducing G<sub>0</sub>/G<sub>1</sub> cell-cycle arrest. GSI-mediated antiproliferative effects were associated with significant reductions in the expression of Notch1, Jagged1, Jagged2, p-Akt and Bcl-2.</p>
</sec>
<sec id="sec18-0300060513485912"><title>Conclusion</title>
<p>Inhibition of the Notch signalling pathway by GSI may be a promising therapeutic approach for the treatment of multiple myeloma.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Multiple myeloma</kwd>
<kwd>Notch signalling pathway</kwd>
<kwd>γ-secretase inhibitor</kwd>
<kwd>phosphoinositide 3-kinase/Akt pathway</kwd>
<kwd>proliferation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513485912" sec-type="intro"><title>Introduction</title>
<p>Multiple myeloma (MM), a haematological malignancy that primarily affects the elderly, is characterized by clonal proliferation of plasma cells. Chemotherapy is the standard treatment for MM. Although the emergence of new drugs, including proteasome inhibitors and antiangiogenesis agents, has greatly improved the prognosis of patients with MM, it remains an incurable disease. The bone marrow microenvironment consists of bone marrow stromal cells, vascular endothelial cells, osteoblasts, osteoclasts, lymphocytes, extracellular matrix proteins, and a variety of secreted cytokines such as interleukin-6, vascular endothelial growth factor, insulin-like growth factor-1 and tumour necrosis factor-α.<sup><xref ref-type="bibr" rid="bibr1-0300060513485912">1</xref>,<xref ref-type="bibr" rid="bibr2-0300060513485912">2</xref></sup> The interaction between MM cells and the bone marrow microenvironment enhances the proliferation of MM cells and induces drug resistance to chemotherapy.<sup><xref ref-type="bibr" rid="bibr3-0300060513485912">3</xref></sup> Therefore, the identification of new targeted therapies for this disease remains an active area of research.<sup><xref ref-type="bibr" rid="bibr4-0300060513485912">4</xref>,<xref ref-type="bibr" rid="bibr5-0300060513485912">5</xref></sup></p>
<p>The Notch signalling pathway is widespread in animals and has been highly conserved during evolution. Notch signalling is initiated by binding of the extracellular domain of Notch to a Notch ligand.<sup><xref ref-type="bibr" rid="bibr6-0300060513485912">6</xref></sup> At present, two Notch ligand families – Delta and Jagged – have been identified.<sup><xref ref-type="bibr" rid="bibr7-0300060513485912">7</xref></sup> The Notch receptors include four family members (Notch1 to Notch4); each member is a large single heterodimeric protein comprised of extracellular, transmembrane and intracellular subunits.<sup><xref ref-type="bibr" rid="bibr8-0300060513485912">8</xref></sup></p>
<p>Notch signalling influences multiple processes that govern normal morphogenesis, programmed cell death, cellular proliferation and differentiation.<sup><xref ref-type="bibr" rid="bibr7-0300060513485912">7</xref>,<xref ref-type="bibr" rid="bibr9-0300060513485912">9</xref>,<xref ref-type="bibr" rid="bibr10-0300060513485912">10</xref></sup> Therefore, Notch signalling dysfunction may inhibit cell differentiation, eventually leading to the malignant transformation of undifferentiated cells and tumourigenesis.<sup><xref ref-type="bibr" rid="bibr11-0300060513485912">11</xref></sup> There is ample evidence linking the Notch signalling pathway with cancer. Overexpression of wild-type Notch receptors, ligands and targets has been observed in an increasing number of solid tumours.<sup><xref ref-type="bibr" rid="bibr12-0300060513485912">12</xref></sup> Similar defects have been found in haematological malignancies, including non-Hodgkin’s lymphoma<sup><xref ref-type="bibr" rid="bibr13-0300060513485912">13</xref></sup> and acute myeloid leukaemia.<sup><xref ref-type="bibr" rid="bibr14-0300060513485912">14</xref></sup> Inhibition of Notch expression by antisense retrovirus or pharmacological blocking of γ-secretase activity induces antineoplastic effects in Notch-expressing transformed cells in vitro.<sup><xref ref-type="bibr" rid="bibr15-0300060513485912">15</xref><xref ref-type="bibr" rid="bibr16-0300060513485912"/>–<xref ref-type="bibr" rid="bibr17-0300060513485912">17</xref></sup> Moreover, inhibition of Notch signalling has been shown to induce apoptosis and to increase sensitivity to chemotherapy in MM cells.<sup><xref ref-type="bibr" rid="bibr18-0300060513485912">18</xref></sup> These findings indicate that inhibition of Notch signalling may represent a new therapeutic approach in the treatment of haematological malignancies. In the present study, the effects of γ-secretase inhibitor (GSI), a Notch signalling inhibitor, on the proliferation of MM cells in vitro and its molecular mechanism of action were investigated.</p>
</sec>
<sec id="sec2-0300060513485912" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0300060513485912"><title>Cell culture</title>
<p>The human RPMI 8226 MM cell line (Shanghai Cell Bank, Shanghai, China) was cultured in RPMI 1640 medium containing 10% fetal bovine serum in a humidified incubator at 37℃ in 5% CO<sub>2</sub>. The culture medium was changed every 2–3 days.</p>
</sec>
<sec id="sec4-0300060513485912"><title>Assessment of proliferation</title>
<p>Cells in the logarithmic growth phase were seeded into 96-well culture plates at a density of 5 × 10<sup>3</sup> cells/well. Then, 100 µl GSI (Enzo Life Sciences, Farmingdale, NY, USA) at final concentrations of 0, 1, 5, 10 and 20 µmol/l was added to the wells. Untreated cells served as controls. A blank control consisting of the drug solvent, dimethyl sulphoxide (DMSO) and GSI without cells was also included in the assay.</p>
<p>After 24, 48 or 72 h, 20 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) (Sigma-Aldrich, St Louis, MO, USA), dissolved in phosphate-buffered saline at a concentration of 20 µmol/l, was added to each well.</p>
<p>Cells were incubated for an additional 4 h at 37℃, centrifuged at 300 <bold><italic>g</italic></bold> for 5 min at room temperature and the supernatant was then collected. Next, 150 µl DMSO was added to the supernatant and the resultant mixture was shaken at room temperature for 10 min. Absorbance was measured at 490 nm in a microplate reader. The cell growth inhibition rate was calculated as follows:
<disp-formula id="disp-formula1-0300060513485912"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math1-0300060513485912"><mml:mrow><mml:mrow><mml:mtext>inhibition rate</mml:mtext><mml:mi> </mml:mi><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mi>%</mml:mi><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mtext>absorbance</mml:mtext><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mtext>treated</mml:mtext><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mi>   </mml:mi><mml:mtext>absorbance</mml:mtext><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mtext>control</mml:mtext><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:mn>1 00</mml:mn><mml:mi>%</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula1-0300060513485912" xlink:href="10.1177_0300060513485912-eq1.tif"/></disp-formula>
</p>
<p>Each stimulation condition was performed in duplicate and repeated three times.</p>
</sec>
<sec id="sec5-0300060513485912"><title>Cell-cycle analysis</title>
<p>The RPMI 8226 MM cells were treated with 0, 5 or 10 µmol/l GSI for 48 h, then collected and washed twice with cold phosphate-buffered saline (pH 7.0). Cell-cycle analysis was performed using a BD FACScan™ flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) as described previously.<sup><xref ref-type="bibr" rid="bibr19-0300060513485912">19</xref></sup> The cells were stained with propidium iodide solution (50 µg/ml) on ice and ≥10 000 cells were analysed for cell-cycle distribution.</p>
</sec>
<sec id="sec6-0300060513485912"><title>Western blot analyses</title>
<p>Western blotting was performed as described previously.<sup><xref ref-type="bibr" rid="bibr19-0300060513485912">19</xref></sup> Cells were treated with GSI at concentrations of 0, 10, 20 and 40 µmol/l for 48 h, or with GSI at a concentration of 10 µmol/l for 24, 48 or 72 h. Cells were then lysed in buffer (pH 7.0) containing freshly prepared protease inhibitors. The protein concentration of the cell lysates was determined using the Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA) with a bovine serum albumin standard. Proteins were subjected to sodium dodecyl sulphate–polyacrylamide gel electrophoresis, electrotransferred to polyvinylidene difluoride membranes and immunoblotted using antibodies to Notch1, Jagged1, Jagged2, phosphorylated Akt (p-Akt) and Bcl-2. The antibody dilutions used were: Notch1, 1 : 250; Jagged1, 1 : 1000; Jagged2, 1 : 1000; p-Akt, 1 : 500; and Bcl-2, 1 : 1000. Antibodies to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) at a dilution of 1 : 3000 were used as a loading control. The appropriate horseradish peroxidase-conjugated secondary antibodies were used and protein bands were visualized using enhanced chemiluminescence. Expression of Notch1, Jagged1 and Jagged2 was measured in cells treated with 0–40 µmol/l GSI for 48 h. Expression of Notch1 and Jagged2 was measured in cells treated with 10 µmol/l GSI for 0–72 h. Expression of Bcl-2 was measured in cells treated with 0–40 µmol/l GSI for 48 h. Expression of p-Akt was measured in cells treated with 0–20 µmol/l GSI for 48 h.</p>
<p>Notch1, Jagged1, Jagged2 and GAPDH monoclonal antibodies and secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA); p-Akt and Bcl-2 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).</p>
</sec>
<sec id="sec7-0300060513485912"><title>Statistical analyses</title>
<p>Data were presented as mean ± SD. Intergroup comparisons were performed using Dunnett’s test, a multiple testing procedure under one-way analysis of variance. Comparisons of means between groups were performed using Student’s <italic>t</italic>-test. A <italic>P</italic>-value &lt; 0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS® software, version 11.5 (SPSS Inc., Chicago, IL, USA).</p>
</sec>
</sec>
<sec id="sec8-0300060513485912" sec-type="results"><title>Results</title>
<sec id="sec9-0300060513485912"><title>Proliferation and cell-cycle analysis</title>
<p>We found that GSI inhibited the proliferation of RPMI 8226 cells in a time- and concentration-dependent manner (<xref ref-type="fig" rid="fig1-0300060513485912">Figure 1</xref>). After 24 h, cell proliferation was significantly inhibited (<italic>P</italic> &lt; 0.05) by GSI at concentrations ≥5 µml/l (<xref ref-type="fig" rid="fig1-0300060513485912">Figure 1</xref>). When compared with the control group, cells treated with 5 or 10 µmol/l GSI had a significantly higher proportion of cells in G<sub>0</sub>/G<sub>1</sub> phase and a lower proportion of cells in S-phase (<italic>P</italic> &lt; 0.05 for both; <xref ref-type="fig" rid="fig2-0300060513485912">Figure 2</xref>).
<fig id="fig1-0300060513485912" position="float"><label>Figure 1.</label><caption><p>Inhibition of proliferation of RPMI 8226 multiple myeloma cells treated with different concentrations of γ-secretase inhibitor (GSI) for different time periods. After 24 h, cell proliferation was significantly inhibited (<italic>P</italic> &lt; 0.05) by GSI at concentrations ≥5 µml/l.</p></caption><graphic xlink:href="10.1177_0300060513485912-fig1.tif"/>
</fig>
<fig id="fig2-0300060513485912" position="float"><label>Figure 2.</label><caption><p>Percentage of cells in different cell-cycle phases in RPMI 8226 multiple myeloma cells treated with different concentrations of γ-secretase inhibitor (GSI) for 48 h. Compared with the control group, cells treated with 5 or 10 µmol/l GSI had significantly higher proportions of cells in G<sub>0</sub>/G<sub>1</sub> phase and lower proportions of cells in S-phase (<italic>P</italic> &lt; 0.05 for both).</p></caption><graphic xlink:href="10.1177_0300060513485912-fig2.tif"/>
</fig></p>
</sec>
<sec id="sec10-0300060513485912"><title>Expression of Notch signalling proteins</title>
<p>Expression of Notch1, Jagged1 and Jagged2 was reduced in a concentration-dependent manner in RPMI 8226 cells treated with GSI for 48 h (<xref ref-type="fig" rid="fig3-0300060513485912">Figure 3</xref>). Treated cells showed significant differences (<italic>P</italic> &lt; 0.05) from control cells at GSI concentrations of 20 and 40 µmol/l for Notch1 and at GSI concentrations of 10, 20 and 40 µmol/l for Jagged1 and Jagged2. In addition, expression of Notch1 and Jagged2 was downregulated in a time-dependent manner in RPMI 8226 cells treated with 10 µmol/l GSI (<xref ref-type="fig" rid="fig4-0300060513485912">Figure 4</xref>); treated cells showed significant differences (<italic>P</italic> &lt; 0.05) from control cells at all time points.
<fig id="fig3-0300060513485912" position="float"><label>Figure 3.</label><caption><p>Expression of (a) Notch1, (b) Jagged1 and (c) Jagged2 Notch signalling proteins detected by Western blotting in RPMI 8226 multiple myeloma cells treated with different concentrations of γ-secretase inhibitor (GSI) for 48 h; data are given relative to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01, compared with 0 µmol/l GSI.</p></caption><graphic xlink:href="10.1177_0300060513485912-fig3.tif"/>
</fig>
<fig id="fig4-0300060513485912" position="float"><label>Figure 4.</label><caption><p>Expression of (a) Notch1 and (b) Jagged2 Notch signalling proteins detected by Western blotting in RPMI 8226 multiple myeloma cells treated with 10 µmol/l of γ-secretase inhibitor (GSI) for different time periods; data are given relative to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH).</p>
<p>*<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01compared with 0 h</p></caption><graphic xlink:href="10.1177_0300060513485912-fig4.tif"/>
</fig></p>
</sec>
<sec id="sec11-0300060513485912"><title>Expression of Bcl-2 and p-Akt</title>
<p>Expression of Bcl-2 and p-Akt was reduced in a concentration-dependent manner in RPMI 8226 cells treated with GSI for 48 h (<xref ref-type="fig" rid="fig5-0300060513485912">Figure 5</xref>). Treated cells showed significant differences (<italic>P</italic> &lt; 0.05) from control cells at GSI concentrations ≥10 µmol/l.
<fig id="fig5-0300060513485912" position="float"><label>Figure 5.</label><caption><p>Expression of (a) Bcl-2 and (b) p-Akt proteins detected by Western blotting in RPMI 8226 multiple myeloma cells treated with different concentrations of γ-secretase inhibitor (GSI) for 48 h; data are given relative to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). *<italic>P</italic> &lt; 0.05 compared with 0 µmol/l GSI.</p></caption><graphic xlink:href="10.1177_0300060513485912-fig5.tif"/>
</fig></p>
</sec>
</sec>
<sec id="sec12-0300060513485912" sec-type="discussion"><title>Discussion</title>
<p>Many studies have shown that overexpression of signalling proteins such as Notch1, Notch2 and Jagged1 is associated with abnormal cell proliferation in myeloma cells.<sup><xref ref-type="bibr" rid="bibr18-0300060513485912">18</xref>,<xref ref-type="bibr" rid="bibr20-0300060513485912">20</xref>,<xref ref-type="bibr" rid="bibr21-0300060513485912">21</xref></sup>Therefore, the Notch signalling pathway has become an attractive candidate for therapeutic intervention in MM.<sup><xref ref-type="bibr" rid="bibr5-0300060513485912">5</xref>,<xref ref-type="bibr" rid="bibr20-0300060513485912">20</xref>,<xref ref-type="bibr" rid="bibr22-0300060513485912">22</xref>,<xref ref-type="bibr" rid="bibr23-0300060513485912">23</xref></sup> Inhibition of Notch1 and Jagged2 expression using phenylhexyl isothiocyanate, a histone deacetylase inhibitor, has been shown to suppress proliferation and induce apoptosis in a concentration- and time-dependent manner in myeloma cells.<sup><xref ref-type="bibr" rid="bibr18-0300060513485912">18</xref>,<xref ref-type="bibr" rid="bibr20-0300060513485912">20</xref></sup> Several studies have examined the effects of blocking the Notch signalling pathway by targeting the c-secretase protein complex to inhibit the activation of Notch receptors.<sup><xref ref-type="bibr" rid="bibr24-0300060513485912">24</xref></sup> It has been shown that inhibition of the c-secretase complex prevents the growth of T-cell acute lymphoblastic leukaemia cell lines, leading to apoptosis.<sup><xref ref-type="bibr" rid="bibr22-0300060513485912">22</xref>,<xref ref-type="bibr" rid="bibr25-0300060513485912">25</xref>,<xref ref-type="bibr" rid="bibr26-0300060513485912">26</xref></sup> The Notch signalling inhibitor GSI has been reported to suppress the growth of several types of tumour cells including sarcoma,<sup><xref ref-type="bibr" rid="bibr27-0300060513485912">27</xref>,<xref ref-type="bibr" rid="bibr28-0300060513485912">28</xref></sup> medulloblastoma,<sup><xref ref-type="bibr" rid="bibr29-0300060513485912">29</xref></sup> ovarian cancer,<sup><xref ref-type="bibr" rid="bibr30-0300060513485912">30</xref></sup> prostate cancer<sup><xref ref-type="bibr" rid="bibr31-0300060513485912">31</xref></sup> and breast cancer.<sup><xref ref-type="bibr" rid="bibr32-0300060513485912">32</xref>,<xref ref-type="bibr" rid="bibr33-0300060513485912">33</xref></sup> In the present study, GSI decreased the expression of Notch1, Jagged1 and Jagged2 in a time- and concentration-dependent manner in RPMI 8226 MM cells. Furthermore, GSI-mediated inhibition of Notch signalling suppressed cell proliferation by inducing G<sub>0</sub>/G<sub>1</sub> cell-cycle arrest. These results are in agreement with other studies demonstrating the antiproliferative and proapopotic effects of GSI in MM cells. Jundt et al.<sup><xref ref-type="bibr" rid="bibr20-0300060513485912">20</xref></sup> found that GSI treatment decreased Jagged1-mediated cell proliferation by 40–70% in myeloma cell lines. Nefedova et al.<sup><xref ref-type="bibr" rid="bibr18-0300060513485912">18</xref></sup> reported that GSI treatment inhibited cell proliferation and induced apoptosis in MM cell lines, and significantly improved the antitumour effects of doxorubicin and melphalan in in vivo mouse models of human MM. Together, these findings suggest the potential therapeutic benefit of GSI in MM.</p>
<p>In the present study, the underlying molecular mechanisms governing the antineoplastic actions of GSI were investigated by measuring its effects on Bcl-2 and p-Akt. GSI-mediated antiproliferative effects were associated with downregulation of the antiapoptotic protein, Bcl-2. This is consistent with the results of Nefedova et al.,<sup><xref ref-type="bibr" rid="bibr18-0300060513485912">18</xref></sup> who reported that the antiproliferative and proapoptotic effects of GSI treatment were associated with downregulation of Hes1, a Notch1 mediator, and the antiapoptotic proteins Bcl-xL and Bcl-2. Furthermore, GSI-mediated apoptosis was mediated by upregulation of the proapoptotic protein Noxa.<sup><xref ref-type="bibr" rid="bibr18-0300060513485912">18</xref></sup> Downregulation of Bcl-xL and Bcl-2 and upregulation of Noxa were also associated with increased sensitivity of MM cells to chemotherapy.<sup><xref ref-type="bibr" rid="bibr18-0300060513485912">18</xref></sup> Whether the combination of GSI with chemotherapy could have synergistic activity against MM requires further investigation.</p>
<p>The phosphoinositide 3-kinase (PI3K)/Akt pathway has been implicated in the oncogenic effects of the Notch signalling pathway.<sup><xref ref-type="bibr" rid="bibr34-0300060513485912">34</xref></sup> The PI3K/Akt pathway plays a key role in promoting cell proliferation by affecting various effector molecules, including apoptotic proteins and cell-cycle regulatory proteins.<sup><xref ref-type="bibr" rid="bibr35-0300060513485912">35</xref>,<xref ref-type="bibr" rid="bibr36-0300060513485912">36</xref></sup> Several studies have reported interaction between the Notch and PI3K/Akt signalling pathways. Liu et al.<sup><xref ref-type="bibr" rid="bibr37-0300060513485912">37</xref></sup> found that the Notch signalling pathway activated the Akt signalling pathway and improved the survival rate of melanoma cells. Palomero et al.<sup><xref ref-type="bibr" rid="bibr38-0300060513485912">38</xref></sup> reported that Hes1 negatively regulated phosphatase and tensin homologue to induce PI3K/Akt upregulation in pre-T acute lymphoblastic leukaemia cells. Thus there is evidence to suggest the reciprocal regulation of Notch and PI3K/Akt signalling pathways: Notch1 not only induces Akt activation but the Akt pathway also induces Notch1. In the present study, GSI-mediated antiproliferative effects were associated with downregulation of p-Akt in MM cells. Nefedova et al.<sup><xref ref-type="bibr" rid="bibr18-0300060513485912">18</xref></sup> also showed that GSI treatment decreased Akt protein expression in MM cells. Further investigation of the molecular mechanisms underlying GSI activity will be valuable in understanding Notch pathway regulation.</p>
<p>In summary, in the present study GSI was shown to inhibit MM cell proliferation in a time- and concentration-dependent manner by inducing G<sub>0</sub>/G<sub>1</sub> cell-cycle arrest. GSI treatment effectively suppressed the expression of the Notch signalling proteins Notch 1, Jagged1 and Jagged2, and was associated with downregulation of p-Akt and Bcl-2. Therefore, inhibition of the Notch signalling pathway by GSI may be a promising therapeutic approach for the treatment of MM.</p>
</sec>
</body>
<back>
<sec id="sec13-0300060513485912"><title>Declaration of conflicting interest</title>
<p>The authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec14-0300060513485912"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0300060513485912"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balakumaran</surname><given-names>A</given-names></name><name><surname>Robey</surname><given-names>PG</given-names></name><name><surname>Fedarko</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis</article-title>. <source>Expert Rev Mol Diagn</source> <year>2010</year>; <volume>10</volume>: <fpage>465</fpage>–<lpage>480</lpage>.</citation></ref>
<ref id="bibr2-0300060513485912"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>B</given-names></name><name><surname>Seckinger</surname><given-names>A</given-names></name><name><surname>Moehler</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment</article-title>. <source>Recent Results Cancer Res</source> <year>2011</year>; <volume>183</volume>: <fpage>39</fpage>–<lpage>86</lpage>.</citation></ref>
<ref id="bibr3-0300060513485912"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group>. <article-title>Bone marrow microenvironment and the identification of new targets for myeloma therapy</article-title>. <source>Leukemia</source> <year>2009</year>; <volume>23</volume>: <fpage>10</fpage>–<lpage>24</lpage>.</citation></ref>
<ref id="bibr4-0300060513485912"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nefedova</surname><given-names>Y</given-names></name><name><surname>Landowski</surname><given-names>TH</given-names></name><name><surname>Dalton</surname><given-names>WS</given-names></name></person-group>. <article-title>Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms</article-title>. <source>Leukemia</source> <year>2003</year>; <volume>17</volume>: <fpage>1175</fpage>–<lpage>1182</lpage>.</citation></ref>
<ref id="bibr5-0300060513485912"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Houde</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines</article-title>. <source>Blood</source> <year>2004</year>; <volume>104</volume>: <fpage>3697</fpage>–<lpage>3704</lpage>.</citation></ref>
<ref id="bibr6-0300060513485912"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Artavanis-Tsakonas</surname><given-names>S</given-names></name><name><surname>Muskavitch</surname><given-names>MA</given-names></name></person-group>. <article-title>Notch: the past, the present, and the future</article-title>. <source>Curr Top Dev Biol</source> <year>2010</year>; <volume>92</volume>: <fpage>1</fpage>–<lpage>29</lpage>.</citation></ref>
<ref id="bibr7-0300060513485912"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Artavanis-Tsakonas</surname><given-names>S</given-names></name><name><surname>Rand</surname><given-names>MD</given-names></name><name><surname>Lake</surname><given-names>RJ</given-names></name></person-group>. <article-title>Notch signaling: cell fate control and signal integration in development</article-title>. <source>Science</source> <year>1999</year>; <volume>284</volume>: <fpage>770</fpage>–<lpage>776</lpage>.</citation></ref>
<ref id="bibr8-0300060513485912"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>B</given-names></name><name><surname>Miele</surname><given-names>L</given-names></name></person-group>. <article-title>Notch and the immune system</article-title>. <source>Immunity</source> <year>1999</year>; <volume>11</volume>: <fpage>653</fpage>–<lpage>663</lpage>.</citation></ref>
<ref id="bibr9-0300060513485912"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miele</surname><given-names>L</given-names></name><name><surname>Osborne</surname><given-names>B</given-names></name></person-group>. <article-title>Arbiter of differentiation and death: notch signaling meets apoptosis</article-title>. <source>J Cell Physiol</source> <year>1999</year>; <volume>181</volume>: <fpage>393</fpage>–<lpage>409</lpage>.</citation></ref>
<ref id="bibr10-0300060513485912"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kopan</surname><given-names>R</given-names></name></person-group>. <article-title>Notch: a membrane-bound transcription factor</article-title>. <source>J Cell Sci</source> <year>2002</year>; <volume>115</volume>: <fpage>1095</fpage>–<lpage>1097</lpage>.</citation></ref>
<ref id="bibr11-0300060513485912"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miele</surname><given-names>L</given-names></name></person-group>. <article-title>Notch signaling</article-title>. <source>Clin Cancer Res</source> <year>2006</year>; <volume>12</volume>: <fpage>1074</fpage>–<lpage>1079</lpage>.</citation></ref>
<ref id="bibr12-0300060513485912"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groth</surname><given-names>C</given-names></name><name><surname>Fortini</surname><given-names>ME</given-names></name></person-group>. <article-title>Therapeutic approaches to modulating Notch signaling: current challenges and future prospects</article-title>. <source>Semin Cell Dev Biol</source> <year>2012</year>; <volume>23</volume>: <fpage>465</fpage>–<lpage>472</lpage>.</citation></ref>
<ref id="bibr13-0300060513485912"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>K</given-names></name><name><surname>Dunleavy</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>WH</given-names></name></person-group>. <article-title>Novel agents for B-cell non-Hodgkin lymphoma: science and the promise</article-title>. <source>Blood Rev</source> <year>2010</year>; <volume>24</volume>: <fpage>69</fpage>–<lpage>82</lpage>.</citation></ref>
<ref id="bibr14-0300060513485912"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia</article-title>. <source>Med Oncol</source> <year>2011</year>; <volume>28</volume>(<supplement>suppl 1</supplement>): <fpage>S483</fpage>–<lpage>489</lpage>.</citation></ref>
<ref id="bibr15-0300060513485912"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leethanakul</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>V</given-names></name><name><surname>Gillespie</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays</article-title>. <source>Oncogene</source> <year>2000</year>; <volume>19</volume>: <fpage>3220</fpage>–<lpage>3224</lpage>.</citation></ref>
<ref id="bibr16-0300060513485912"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jundt</surname><given-names>F</given-names></name><name><surname>Anagnostopoulos</surname><given-names>I</given-names></name><name><surname>Förster</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma</article-title>. <source>Blood</source> <year>2002</year>; <volume>99</volume>: <fpage>3398</fpage>–<lpage>3403</lpage>.</citation></ref>
<ref id="bibr17-0300060513485912"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weijzen</surname><given-names>S</given-names></name><name><surname>Rizzo</surname><given-names>P</given-names></name><name><surname>Braid</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells</article-title>. <source>Nat Med</source> <year>2002</year>; <volume>8</volume>: <fpage>979</fpage>–<lpage>986</lpage>.</citation></ref>
<ref id="bibr18-0300060513485912"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nefedova</surname><given-names>Y</given-names></name><name><surname>Sullivan</surname><given-names>DM</given-names></name><name><surname>Bolick</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy</article-title>. <source>Blood</source> <year>2008</year>; <volume>111</volume>: <fpage>2220</fpage>–<lpage>2229</lpage>.</citation></ref>
<ref id="bibr19-0300060513485912"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways</article-title>. <source>J Hematol Oncol</source> <year>2008</year>; <volume>1</volume>: <fpage>6</fpage>–<lpage>6</lpage>.</citation></ref>
<ref id="bibr20-0300060513485912"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jundt</surname><given-names>F</given-names></name><name><surname>Pröbsting</surname><given-names>KS</given-names></name><name><surname>Anagnostopoulos</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells</article-title>. <source>Blood</source> <year>2004</year>; <volume>103</volume>: <fpage>3511</fpage>–<lpage>3515</lpage>.</citation></ref>
<ref id="bibr21-0300060513485912"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nefedova</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Alsina</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines</article-title>. <source>Blood</source> <year>2004</year>; <volume>103</volume>: <fpage>3503</fpage>–<lpage>3510</lpage>.</citation></ref>
<ref id="bibr22-0300060513485912"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>AP</given-names></name><name><surname>Nam</surname><given-names>Y</given-names></name><name><surname>Wolfe</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling</article-title>. <source>Mol Cell Biol</source> <year>2003</year>; <volume>23</volume>: <fpage>655</fpage>–<lpage>664</lpage>.</citation></ref>
<ref id="bibr23-0300060513485912"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skrtić</surname><given-names>A</given-names></name><name><surname>Korać</surname><given-names>P</given-names></name><name><surname>Krišto</surname><given-names>DR</given-names></name><etal/></person-group>. <article-title>Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance</article-title>. <source>Hum Pathol</source> <year>2010</year>; <volume>41</volume>: <fpage>1702</fpage>–<lpage>1710</lpage>.</citation></ref>
<ref id="bibr24-0300060513485912"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shih IeM</surname></name><name><surname>Wang</surname><given-names>TL</given-names></name></person-group>. <article-title>Notch signaling, gamma-secretase inhibitors, and cancer therapy</article-title>. <source>Cancer Res</source> <year>2007</year>; <volume>67</volume>: <fpage>1879</fpage>–<lpage>1882</lpage>.</citation></ref>
<ref id="bibr25-0300060513485912"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chadwick</surname><given-names>N</given-names></name><name><surname>Zeef</surname><given-names>L</given-names></name><name><surname>Portillo</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Identification of novel Notch target genes in T cell leukaemia</article-title>. <source>Mol Cancer</source> <year>2009</year>; <volume>8</volume>: <fpage>35</fpage>–<lpage>35</lpage>.</citation></ref>
<ref id="bibr26-0300060513485912"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>I</given-names></name><name><surname>Minter</surname><given-names>LM</given-names></name><name><surname>Telfer</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases</article-title>. <source>Blood</source> <year>2009</year>; <volume>113</volume>: <fpage>1689</fpage>–<lpage>1698</lpage>.</citation></ref>
<ref id="bibr27-0300060513485912"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curry</surname><given-names>CL</given-names></name><name><surname>Reed</surname><given-names>LL</given-names></name><name><surname>Golde</surname><given-names>TE</given-names></name><etal/></person-group>. <article-title>Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells</article-title>. <source>Oncogene</source> <year>2005</year>; <volume>24</volume>: <fpage>6333</fpage>–<lpage>6344</lpage>.</citation></ref>
<ref id="bibr28-0300060513485912"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Setoguchi</surname><given-names>T</given-names></name><name><surname>Hirotsu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation</article-title>. <source>Br J Cancer</source> <year>2009</year>; <volume>100</volume>: <fpage>1957</fpage>–<lpage>1965</lpage>.</citation></ref>
<ref id="bibr29-0300060513485912"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Mikolaenko</surname><given-names>I</given-names></name><name><surname>Elhassan</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Notch1 and notch2 have opposite effects on embryonal brain tumor growth</article-title>. <source>Cancer Res</source> <year>2004</year>; <volume>64</volume>: <fpage>7787</fpage>–<lpage>7793</lpage>.</citation></ref>
<ref id="bibr30-0300060513485912"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780</article-title>. <source>Biochem Biophys Res Commun</source> <year>2010</year>; <volume>393</volume>: <fpage>144</fpage>–<lpage>149</lpage>.</citation></ref>
<ref id="bibr31-0300060513485912"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways</article-title>. <source>J Cell Biochem</source> <year>2010</year>; <volume>109</volume>: <fpage>726</fpage>–<lpage>736</lpage>.</citation></ref>
<ref id="bibr32-0300060513485912"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondratyev</surname><given-names>M</given-names></name><name><surname>Kreso</surname><given-names>A</given-names></name><name><surname>Hallett</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer</article-title>. <source>Oncogene</source> <year>2012</year>; <volume>31</volume>: <fpage>93</fpage>–<lpage>103</lpage>.</citation></ref>
<ref id="bibr33-0300060513485912"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rasul</surname><given-names>S</given-names></name><name><surname>Balasubramanian</surname><given-names>R</given-names></name><name><surname>Filipović</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells</article-title>. <source>Br J Cancer</source> <year>2009</year>; <volume>100</volume>: <fpage>1879</fpage>–<lpage>1888</lpage>.</citation></ref>
<ref id="bibr34-0300060513485912"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>Targeting the phosphoinositide 3-kinase pathway in cancer</article-title>. <source>Nat Rev Drug Discov</source> <year>2009</year>; <volume>8</volume>: <fpage>627</fpage>–<lpage>644</lpage>.</citation></ref>
<ref id="bibr35-0300060513485912"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abedini</surname><given-names>MR</given-names></name><name><surname>Muller</surname><given-names>EJ</given-names></name><name><surname>Bergeron</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein</article-title>. <source>Oncogene</source> <year>2010</year>; <volume>29</volume>: <fpage>11</fpage>–<lpage>25</lpage>.</citation></ref>
<ref id="bibr36-0300060513485912"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>SM</given-names></name><name><surname>Perez</surname><given-names>DA</given-names></name><name><surname>Polley</surname><given-names>MY</given-names></name><etal/></person-group>. <article-title>Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival</article-title>. <source>J Neurooncol</source> <year>2010</year>; <volume>97</volume>: <fpage>33</fpage>–<lpage>40</lpage>.</citation></ref>
<ref id="bibr37-0300060513485912"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>ZJ</given-names></name><name><surname>Xiao</surname><given-names>M</given-names></name><name><surname>Balint</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression</article-title>. <source>Cancer Res</source> <year>2006</year>; <volume>66</volume>: <fpage>4182</fpage>–<lpage>4190</lpage>.</citation></ref>
<ref id="bibr38-0300060513485912"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palomero</surname><given-names>T</given-names></name><name><surname>Dominguez</surname><given-names>M</given-names></name><name><surname>Ferrando</surname><given-names>AA</given-names></name></person-group>. <article-title>The role of the PTEN/AKT pathway in NOTCH1-induced leukemia</article-title>. <source>Cell Cycle</source> <year>2008</year>; <volume>7</volume>: <fpage>965</fpage>–<lpage>970</lpage>.</citation></ref>
</ref-list>
</back>
</article>